Japan multicenter prospective study: FDG-PET/CT as imaging biomarker to evaluate the response of Axitinib for Sunitinib failed metastatic renal cell carcinoma patients.
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2014
Price : $35 *
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Pfizer
- 19 Jan 2014 According to University Hospital Medical Information Network-Japan record, status changed from not yet recruiting to recruiting.
- 16 Dec 2013 New trial record